蛋白质组和转录组概况的综合分析揭示了与癌症相关的全癌症途径和分子生物标志物
Guo-Sheng Hu1, Zao-Zao Zheng2, Yao-Hui He3
1Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University, Fuzhou, China; State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, Fujian, China; Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, Fujian, China; Xiang An Biomedicine Laboratory, School of Pharmaceutical Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, Fujian, China.
这项研究整合了13种癌症类型的蛋白质基因和转录基因数据,以确定关键的失调基因和途径. 研究结果揭示了新的泛癌诊断生物标志物,预后模型,以及精确瘤学的潜在药物标.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 蛋白质组学是指蛋白质组学.
- 生物信息学是一种生物信息学.
背景情况:
- 了解癌症需要分析精确瘤学的基因和途径失调.
- 整合蛋白质组和转录组数据为胰腺癌分析提供了一种系统的方法.
研究的目的:
- 通过整合蛋白质组和转录组数据,在多种癌症类型中识别失调的基因和途径.
- 发现新的泛癌诊断生物标志物,预后标志物和潜在的治疗点.
主要方法:
- 编制和整合了来自13种癌症类型的蛋白质组 (2404个样本) 和转录组 (7752个样本) 数据集.
- 进行正常和瘤组织之间的比较分析,以及跨TNM阶段的比较分析.
- 开发了预后风险分层模型,并确定了潜在的药物点.
主要成果:
- 确定了失调的途径,包括mRNA剪接,干扰素,脂肪酸代谢和补充凝血级联.
- 发现了泛癌上调和下调基因 (PCUG/PCDG),其中RRM2和ADH1B作为强大的生物标志物.
- 在癌症进展中经常发现补体凝血和上皮-介质细胞过渡的失调.
- 确定了持续上调/下调的泛癌蛋白质 (PCCUP/PCCDP),并开发了有效的预后模型.
- 预测的小分子抑制剂针对CDK,HDAC,MEK,JAK和PI3K作为潜在的泛癌治疗方法.
结论:
- 组合蛋白质组和转录组数据对于识别胰腺癌的诊断和预后标志物具有强大作用.
- 这项研究为癌症进展提供了宝贵的见解,并支持药物重定向策略.
- 为癌症诊断,分期和风险评估开发的网络工具提高了临床效用.
更多相关视频
09:00A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
Published on: April 18, 2025
10:37Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
Published on: November 15, 2017
相关概念视频
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
